Skip to main content

Severe hypoglycaemia after long‐acting octreotide in a patient with an unrecognized malignant insulinoma

Buy Article:

$43.00 plus tax (Refund Policy)

Insulinomas are the most common hormone‐producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long‐acting octreotide.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: hypoglycaemia; insulinoma; octreotide

Document Type: Research Article

Affiliations: Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia

Publication date: 01 June 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more